Repertoization Team: Kate Birch, RSHom(NA), CCH, C.HPx, Jiuan Heng, CCH, RSHom(NA), C.HPx, Crystal Morse, BCN, DNM, C.HPx, Shelly Garrison, CCH, C.HPx, Cheryl Wood, CCH, RSHom(NA), C.HPx, Gabriella Calvi-Rooney, B.S., DSH, C.HP,x Ursula Dobelmann, CCH, C.HP.x.
Source: Coronavirus was first identified in Wuhan, China, in December 2019. Thirteen samples were shipped to a third-party lab in the US for authentication. The nosode, Novus-CV, was made from samples that passed authentication. The samples were from nasopharyngeal swabs, alveolar lavage fluid, and sputum of active human cases of CV. This is a nosode made from the mutated form of the virus; one that has been passed from human to human. The nosode was potentized in the traditional way of trituration, dilution, and succussion.
Continue reading
Authors: Birch, K., Heng, J., Morse, C., Garrison, S., Wood, C., Calvi-Rooney, G., Dobelmann, U.
Data analysis team: Miller, A., Chinery, A., Iger, J., Beierle, K., Wadely, K., Mearns, M., Hunter, R., Schoenecker, S., Garland. S.
Keywords: Homeoprophylaxis (HP), Proving, Coronavirus, Immunity, Infectious Disease, Nosode.
In March of 2020 FHCi embarked on the research of Coronavirus Nosode for the prevention and treatment of Covid-19. Three papers were published as a result of this research. This is the first paper.
Continue reading
Determining the safety, effects, and efficacy of Novus-CV in homoeopathic dilution in humans for Covid-19 disease prevention
Keywords: Adverse Events, Coronavirus, Homoeopathy, Homoeoprophylaxis (HP), Long-term Health Outcomes, Infectious Disease, Nosodes, Public Health Program
Authors: Birch, K., Heng, J., Morse, C., Garrison, S., Wood, C., Calvi-Rooney, G., Dobelmann, U.
Data analysis team: Miller, A., Chinery, A., Iger, J., Beierle, K., Wadely, K., Mearns, M., Hunter, R., Schoenecker, S., Garland. S.
Keywords: Adverse Events, Coronavirus, Homoeopathy, Homoeoprophylaxis (HP), Long-term Health Outcomes, Infectious Disease, Nosodes, Public Health Program.
Continue reading